Conference Program

7th Saudi Lymphoma/Myeloma and 10th Hematopathology Overview

9–10 October 2026 8:00 AM – 6:30 PM (KSA) Novotel Dhahran Hotel & Residences
Download the PDF Directions Details
08:00 – 08:30
Registration
Break
08:30 – 08:35
Welcome Remarks and Program Overview
Mubarak Almansour
Highlight
08:35
Session One
Moderators: Abdullah Alsaleh / Solaf Kanfar / Wael Alanazi
Session
08:35 – 09:00
What are the frontline treatment strategies for Multiple Myeloma in 2026 for transplant-eligible and ineligible?
Khalil Farsi (OM)
Session
09:00 – 09:25
RRMM Current Landscape and Future Directions
Omar Abduljalil (KSA)
Session
09:25 – 09:50
CAR-T vs. Bispecific therapy for relapsed Multiple Myeloma, which one and when?
Majed Alahmadi (KSA)
Session
09:50 – 10:00
Discussion
Session
10:00 – 10:15
Coffee Break
Break
10:15 – 10:45
Role and sequencing of BCMA agents in RR Multiple Myeloma
GSK Satellite Symposium
Ayman Alhejazi (KSA)
Symposium
10:45 – 11:30
Roche Satellite Symposium
Reyad Dada / Ghazi Alotaibi / Manar Abdulbaqi
Introduction – Saud Asubait
Anchoring the standard of care in first-line DLBCL
Charting the changing currents in second-line treatments
Mapping the treatment journey in heavily pretreated patients
Symposium
11:30 – 13:30
Juma'ah Prayer and Lunch Break
Prayer at 12:00 PM
Break
13:30
Session Two
Moderators: Musa Alzahrani / Abdulkareem AlGarni / Aamer Bugnah
Session
13:30 – 14:00
Frontline mantle cell lymphoma: do we still need autologous transplant?
Toby Eyre (UK)
Session
14:00 – 14:30
Local Experience/Updates in DLBCL
Mohammed Aldarweesh (KSA)
Session
14:30 – 15:00
Follicular lymphoma: second-line therapy is being rewritten
Ann Lacasce (USA)
Session
15:00 – 15:15
Coffee Break
Break
15:15
Session Three
Moderators: Ayman Alhejazi / Ghazi Alotaibi / Omar Abduljalil
Session
15:15 – 15:45
Real-World Large-Cohort Report of Equecabtagene Autoleucel in R/R MM from FUMANBA-1
IASO Satellite Symposium
Prof. Lu Jin (CHN)
Symposium
15:45 – 16:15
Smoldering Multiple Myeloma
Maria Victoria Mateos (ES)
Session
16:15 – 16:45
Summary of new response criteria in Multiple Myeloma
Shaji Kumar (USA)
Session
16:45 – 17:05
CAR-T in KSA: Advancing the Future of Multiple Myeloma Care
Johnson & Johnson Satellite Symposium · Moderator: Abdullah Alsaleh
Ayman Alhejazi (KSA)
Symposium
17:05 – 17:15
Coffee Break
Break
17:15
Session Four
Moderators: Ayman Ibrahim / Manar Abdulbaqi / Khalid Aldosari
Session
17:15 – 17:45
Early-stage Hodgkin Lymphoma: How immunotherapy is changing the treatment landscape.
Stephen Ansell (USA)
Session
17:45 – 18:15
R/R CLL: best sequencing strategy
John Allan (USA)
Session
18:15 – 18:45
Best management strategy in R/R T-cell-rich B-cell lymphoma
Tycel Phillips (USA)
Session
18:45
Discussion – End of Day 1
Highlight
08:30 – 08:35
Welcome Remarks and Program Overview
Ahmed Al-Bahrani, MD
Highlight
08:35
Session One
Moderators: Dr. Mohammed Al Mohammadi and Dr. Sameera Alsafwani
Session
08:35 – 08:55
Expect the unexpected: intriguing cases in hematopathology
Reem Alrabeh, MD
Session
08:55 – 09:15
Flowcytometry in the diagnosis of hematological malignancies
Mariam Alghazal, MD
Session
09:15 – 09:35
Diagnostic classification of myeloid neoplasm: WHO 5th vs ICC 2022 for myeloid neoplasm
Maher Aljohani, MD
Session
09:35 – 09:45
Discussion
Session
09:45 – 10:00
Coffee Break
Break
10:00
Session Two
Moderators: Dr. Abdulmajeed Al Abdullateef and Dr. Fatimah Al Ghanim
Session
10:00 – 10:20
From screening tests to precision diagnosis of acquired and congenital coagulopathies
Rabab Al Dawood, MD
Session
10:20 – 10:40
Diagnostic strategies and challenges in platelet function testing
Rahaf Altahan, MD
Session
10:40 – 11:00
The Evolving landscape of factor XIII testing: method, pitfalls, and best practices
Mohammed AlSharif, MD
Session
11:00 – 11:20
Transfusion challenges in multiple myeloma
Ammar Alsughayir, MD
Session
11:20 – 11:30
Discussion
Session
11:30 – 13:00
Prayer and Lunch Break
Prayer at 12:00 PM
Break
13:00
Session Three
Moderators: Dr. Ahmed Al Bahrani and Dr. Haifa Almuhtaresh
Session
13:00 – 13:20
Distinguishing hairy cell leukemia from splenic marginal zone lymphoma: diagnostic pearls for the hematopathologist
Mona Alfaraj, MD
Session
13:20 – 13:40
New updates in AML, Measurable residual disease a consensus approach from ELN-MRD working group
Heba Raslan, MD
Session
13:40 – 14:00
MPD – Myelofibrosis
Ahmed Al Rajjal, MD
Session
14:00 – 14:10
Discussion
Session
14:10 – 14:25
Coffee Break
Break
14:25
Session Four
Moderators: Dr. Mukhtar Buhlaiga and Dr. Naif Bin Muhanaa
Session
14:25 – 14:45
The ultimate Transfusion puzzle: strategies for anti-Rh17 management.
Fatma Aldarweesh, MD
Session
14:45 – 15:05
Evolving Practice in Transplant & Cellular Therapies
Ahmed Al-Bahrani, MD
Session
15:05 – 15:25
Updates on mismatch-unrelated hematopoietic stem cell transplantation
Mohammad Awaji, PhD
Session
15:25 – 15:35
Discussion and Closing Remarks
Ammar Alsughayir, MD
Session
15:35
End of Day 2
Highlight